---
title: "Rivaroxaban After Catheter Ablation for Atrial Fibrillation Compared With Aspirin"
id: "annals-of-internal-medicine-32-after-successful-catheter-ablation-for-af-rivaroxaban-did-not-reduce-a-composite-of-stroke-or-systemic-embolism-vs-aspirin-at-36-mo"
canonical_url: "https://medichelpline.com/clinical-feed/annals-of-internal-medicine-32-after-successful-catheter-ablation-for-af-rivaroxaban-did-not-reduce-a-composite-of-stroke-or-systemic-embolism-vs-aspirin-at-36-mo"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "Annals of Internal Medicine (ACP)"
source_url: "https://www.acpjournals.org/doi/abs/10.7326/ANNALS-25-05629-JC?af=R"
published_at: "2026-03-03T08:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Rivaroxaban After Catheter Ablation for Atrial Fibrillation Compared With Aspirin
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/annals-of-internal-medicine-32-after-successful-catheter-ablation-for-af-rivaroxaban-did-not-reduce-a-composite-of-stroke-or-systemic-embolism-vs-aspirin-at-36-mo
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** Annals of Internal Medicine (ACP)
- **Source URL:** [Original Journal Publication](https://www.acpjournals.org/doi/abs/10.7326/ANNALS-25-05629-JC?af=R)
- **Published At:** 2026-03-03T08:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 03 Mar 2026. The item focuses on After successful catheter ablation for AF, rivaroxaban did not reduce a composite of stroke or systemic embolism vs. aspirin at 36 mo. Review the original article for the full source wording and details.
## Clinical Analysis & Structured Key Points
Annals of Internal Medicine (ACP) published a clinical update in Research Highlights on 03 Mar 2026. The item focuses on After successful catheter ablation for AF, rivaroxaban did not reduce a composite of stroke or systemic embolism vs. aspirin at 36 mo. Review the original article for the full source wording and details.
## Related Clinical Research

- [Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US](https://medichelpline.com/clinical-feed/medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs.md)
- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)
- [Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials](https://medichelpline.com/clinical-feed/plos-medicine-19-early-aspirin-withdrawal-versus-dual-antiplatelet-therapy-in-high-risk-patients-after-percutaneous-coronary-intervention-meta-analysis-of-randomized-trials.md)
- [Daily Aspirin Does Not Lower Colorectal Cancer Risk, Review Finds](https://medichelpline.com/clinical-feed/medical-news-today-49-daily-aspirin-does-not-lower-colorectal-cancer-risk-review-finds.md)
- [New oral anticoagulants linked to slower cognitive decline in Alzheimer’s patients with AFib](https://medichelpline.com/clinical-feed/medical-news-today-0-new-oral-anticoagulants-may-help-slow-cognitive-decline-in-alzheimer-s-disease.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.